Free Trial
→ Palantir and Wall Street are in on it… (From Monument Traders Alliance) (Ad)tc pixel Free IBB Stock Alerts
NASDAQ:IBB

iShares Biotechnology ETF (IBB) Price, Holdings, & News

iShares Biotechnology ETF logo
$204.41 -2.08 (-1.01%)
As of 02:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

About iShares Biotechnology ETF (NASDAQ:IBB)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$204.07
▼
$206.93
50-Day Range
$185.91
▼
$216.96
52-Week Range
$149.09
▼
$217.12
Volume
677,657 shs
Average Volume
1.65 million shs
Market Capitalization
$10.47 billion
Assets Under Management
$10.84 billion
Dividend Yield
0.17%
Net Expense Ratio
0.44%
Aggregate Rating
Moderate Buy

ETF Overview

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

iShares Biotechnology ETF Expenses

TypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.44%0.55%0.57%0.54%0.53%
Other Expenses0.00%0.52%0.53%0.38%0.54%
Total Expense0.44%0.76%0.75%0.69%0.73%
Fee Waiver0.00%-0.85%-0.67%-0.41%-0.68%
Net Expense0.44%0.58%0.63%0.61%0.60%
Receive IBB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IBB ETF News Headlines

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
October 11 at 7:09 PM  |  fool.comhttps://www.fool.com/coverage/etfs/2026/10/11/which-ishares-healthcare-etf-is-the-better-buy-biotech-focused-ibb-or-broad-iyh/
Traders Purchase Large Volume of Put Options on iShares Biotechnology ETF (NASDAQ:IBB)
October 10 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104320
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially a power company. The firm expects up to 190 MW of Nordic data center capacity approaching ready-for-service status by 2027-2028, as similar capacity has recently been valued at roughly $1.7 million to $2 million per MW annually. Google plans to invest $15 billion in Finland's AI infrastructure, with Cerebras also building a 165 MW facility nearby.tc pixel
October 12 at 1:00 AM  |  The Tomorrow Investor (Ad)
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB
October 5, 2026  |  fool.comhttps://www.fool.com/coverage/etfs/2026/10/05/better-healthcare-etf-vanguard-s-broad-vht-vs-the-ishares-biotechnology-focused-ibb/
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/big-pharma-got-its-tariff-exemption-the-biotech-etf-barely-blinked/
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/big-pharma-got-its-tariff-exemption-the-biotech-etf-barely-blinked/?utm_source=snapi
See More Headlines

IBB ETF - Frequently Asked Questions

iShares Biotechnology ETF's stock was trading at $168.77 on January 1st, 2026. Since then, IBB stock has increased by 21.0% and is now trading at $204.2180.

iShares Biotechnology ETF's stock split on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were payable to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Top institutional investors of iShares Biotechnology ETF include Apella Capital LLC (0.11%), Toth Financial Advisory Corp (0.08%), Neville Rodie & Shaw Inc. (0.08%) and Monument Capital Management (0.06%).

Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Fund Details

Issuer
iShares
Fund Name
iShares Biotechnology ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:IBB
Inception Date
2/5/2001
Fund Manager
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
NYSE Biotechnology Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
248

Fund Statistics

Assets Under Management
$10.84 billion
Average Daily Volume
$1.73 million
Discount/Premium
0.19%

Administrator, Advisor and Custodian

Administrator
J.P. Morgan Chase Bank, N.A.
Advisor
BlackRock Fund Advisors
Custodian
JPMorgan Chase Bank, N.A.
Distributor
BlackRock Investments, LLC
Transfer Agent
J.P. Morgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Latour Trading

Options

Optionable
Optionable
Options Volume
3,914
Put Options
2,797
Call Options
1,117
Short Interest
11,555,499 shs

Miscellaneous

Outstanding Shares
51,200,000
Beta
0.70
Creation Unit
50,000
Creation Fee
$614.00
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Top 10 IBB Holdings

Full Holdings Details

IBB Sector Exposure

IBB Industry Exposure


This page (NASDAQ:IBB) was last updated on 10/12/2026 by MarketBeat.com Staff.
From Our Partners
HOST Just Entered the AI Data Center Race in a BIG Way
Host Digital Inc. (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp. on September 1...
Trading Wire | Sponsoredtc pixel
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th
Marc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...
Chaikin Analytics | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Fox News: Wall Street Can Seize Your Retirement
Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...
Monetary Gold | Sponsoredtc pixel
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...
Monument Traders Alliance | Sponsoredtc pixel